| Literature DB >> 24223352 |
Farhad Etezadi1, Kourosh Karimi Yarandi, Aylar Ahangary, Hajar Shokri, Farsad Imani, Saeid Safari, Mohammad Reza Khajavi.
Abstract
BACKGROUND: The incidence of transient neurologic symptoms (TNS) after spinal anesthesia with lidocaine is reported as high as 40%.Entities:
Keywords: Anesthetics; Local; Neurologic Manifestations
Year: 2013 PMID: 24223352 PMCID: PMC3821142 DOI: 10.5812/aapm.6916
Source DB: PubMed Journal: Anesth Pain Med ISSN: 2228-7523
Demographic Characteristics and Important Risk Factors among The Four Groups
| Group 1: Lidocaine + Sprotte | Group 2: Lidocaine + Quincke | Group 3: Bupivacaine + Sprotte | Group 4: Bupivacaine + Quincke | |
|---|---|---|---|---|
| Age, y | 47.1 | 46.0 | 46.2 | 46.3 |
| Sex, male/female | 49/13 | 51/12 | 51/11 | 54/9 |
| Duration of surgery, min | 64.1 | 64.2 | 62.1 | 59.6 |
| Position, supine/lithotomy | 33/29 | 33/30 | 35/27 | 37/26 |
| Type of surgery | ||||
| Varicocele | 11 | 11 | 12 | 13 |
| TUL and TUR | 29 | 30 | 27 | 26 |
| Herniorrhaphy | 8 | 9 | 9 | 9 |
| Surgical fixation of lower extremity fracture a | 14 | 13 | 14 | 15 |
Abbreviations: TUL, transurethral lithotripsy; TUR, Transurethral resection of the prostate.
aOnly the cases with fractures below the knee were included.
Type of Surgery and Patients’ Position
| Type of Surgery/Position | Supine | Lithotomy | Total | Duration of Surgery, Minutes |
|---|---|---|---|---|
| 47 | - | 47 | 60 ± 11 | |
| - | 112 | 112 | 45 ± 18 | |
| 35 | - | 35 | 70 ± 12 | |
| 56 | - | 56 | 95 ± 17 |
Abbreviations: TUL, transurethral lithotripsy; TUR, transurethral resection of the prostate.
The Incidence of Transient Neurologic Symptoms (TNS) According to the Drug and the Type of Needle Used
| Complication | Lidocaine | Bupivacaine | Quincke | Sprotte | Total |
|---|---|---|---|---|---|
| 85 (68) | 14 (11) | 58 (46) | 41 (33) | 99 (39.6) | |
| 0.003 | 0.003 | 0.7 | 0.7 |
The Incidence of TNS in the Four Groups of the Study
| Incidence/Group | Group 1: Lidocaine + Sprotte | Group 3: Lidocaine + Quincke | Group 2: Bupivacaine + Sprotte | Group 4: Bupivacaine + Quincke |
|---|---|---|---|---|
| 35 (56) | 50 (79) | 6 (9) | 8 (13) |
Multivariate Analysis of Different Influencing Factors
| Relative Risk (95% CI) | P value | |
|---|---|---|
| 6.18 (4.7-7.9) | 0.003 | |
| 1.39 (0.7-1.8) | 0.7 | |
| 4.1 (3.0-4.9) | 0.008 | |
| 1.63 (1.1-2.3) | 0.04 |